Slide 1: ARS Pharmaceuticals Third Quarter 2025 Financial Results
NASDAQ: SPRY ARS Pharmaceuticals Third Quarter 2025 Financial Results Conference Call November 10, 2025
Slide 2: Forward-looking statements
Forward-looking statements Statements in this presentation that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation include, without limitation, statements reg
Slide 3: Strong neffy sales growth to date, with significant near-term levers for 2026
Strong neffy sales growth to date, with significant near-term levers to unlock even greater sales growth in 2026 neffy US quarterly net sales in 2025 Near-term activities expected to further accelerate U.S. growth $ millions of USD $31.3 ARS Pharmaceuticals, Inc. Investor Presentation – November 202
Slide 4: neffy investment in DTC is significantly increasing consumer awareness
neffy investment in DTC is significantly increasing consumer awareness with early ROI measures on track to benchmarks ARS Pharmaceuticals, Inc. Investor Presentation – November 2025 DTC impact on aided consumer awareness of neffy (%)1 80% of patients 89% 20% 2.8x increase 56% are very likely or extr
Slide 5: "Get neffy on Us" virtual prescriber with $0 co-pay launched
“Get neffy on Us” virtual prescriber with a $0 co-pay launched in November 2025 to reduce patient burden 72% of patients are ARS Pharmaceuticals, Inc. Investor Presentation – November 2025 interested in a virtual prescriber option1 $0 co-pay for commercially eligible patients $0 visit fee <5 to 10 m
Slide 6: Continued strong growth in prescribing breadth by HCPs
Continued strong growth in prescribing breadth by HCPs Growing breadth of HCPs prescribing 18,000 ARS Pharmaceuticals, Inc. Investor Presentation – November 2025 Total direct reach to ~20,000 HCPs representing ~55% of epinephrine Rx from # of HCPs that have prescribed neffy all HCPs • ARS sales orga
Slide 7: neffy is already expanding the epinephrine market into new patient segments
neffy is already expanding the epinephrine market into new patient segments beyond those who already fill autoinjector Rx Source of neffy patients by segment Addressable US (September 2025)1 Segment Size (Patients) ARS Pharmaceuticals, Inc. Investor Presentation – November 2025 100% 26% of neffy pat
Slide 8: Surveys of neffy users indicate high satisfaction and higher intention to refill
Surveys of neffy users indicate a high satisfaction and higher intention to refill versus EAIs, contributing to market expansion 95% (12 ARS Pharmaceuticals, Inc. Investor Presentation – November 2025 % of actual users likely to refill neffy1 to 24 month expiry from product receipt) of neffy users r
Slide 9: Strong financial position to invest into the growth of neffy
Strong financial position to invest into the growth of neffy Q3 2025 Highlights $288.2M ARS Pharmaceuticals, Inc. Investor Presentation – November 2025 in cash, cash equivalents and short-term investments as of September 30, 2025 $32.5M total revenue RA Capital and OMERS Life Sciences $100M debt fac
Slide 10: Q&A
Q&A AiR?